42 results about "Chemotherapy regimen" patented technology

The invention discloses a tumor disease assessment method based on big data, and particularly relates to the technical field of tumor disease assessment. Medical data and living habit data of a patient are collected through multiple data interfaces, integration is carried out through preprocessing and a multi-modal data fusion technology, tumor microenvironment features and drug metabolism features are extracted, a comprehensive feature vector is generated, the effectiveness of a chemotherapy regimen is predicted by using a machine learning model, and when the effectiveness of the chemotherapy regimen is low, the chemotherapy regimen is identified. Newest clinical tests and drug data are introduced regularly, model parameters are dynamically optimized in combination with the chemotherapy regimen improvement effect, it is ensured that the model reflects the newest clinical progress in real time, the problems of model updating lag and drug innovation mismatching are effectively solved, the accuracy and effectiveness of a treatment regimen are improved, and the treatment cost is reduced. And meanwhile, side effects caused by blind attempts are reduced, and powerful support is provided for personalized precise medical treatment.

The invention relates to a recombinant complement protein and application thereof in preparation of anti-leukemia drugs, and belongs to the technical field of biological medicines. The invention discloses a method for treating acute leukemia by single drug, namely injecting recombinant C1QBP protein, which has a remarkable effect on treating acute leukemia, can be used for remarkably inhibiting proliferation of leukemia cells in marrow, spleen and peripheral blood of a hematopoietic system and also inhibiting infiltration of the leukemia cells in extramedullary organs (skin and the like), so that the whole-body tumor load is reduced, and the curative effect of treating acute leukemia is improved. The lifetime of leukemia mice is obviously prolonged. The recombinant C1QBP protein is combined with a clinical first-line chemotherapy regimen for use, has a synergistic effect, has a stronger effect of inhibiting leukemia cell proliferation compared with a single chemotherapy drug, can significantly prolong the lifetime of leukemia mice, and plays a role in reducing toxicity and enhancing efficacy. The invention proves that the complement C1Q binding protein has the effect of treating leukemia for the first time, provides a preparation method and a drug combination scheme, and has relatively high clinical transformation prospect and application value.

The invention discloses a hypopharyngeal carcinoma induced chemotherapy prognosis prediction and treatment scheme processing method and device and a medium, and can be applied to the technical field of big data processing. According to the method, after a first CT image, first clinical text information, a first induction chemotherapy regimen selected by a hypopharyngeal carcinoma patient in historical initial treatment and historical multi-modal information of a plurality of hypopharyngeal carcinoma patients in historical initial treatment before induction chemotherapy are obtained, a preset model is trained through the historical multi-modal information, wherein the historical multi-modal information comprises a first CT image, first clinical text information, the first induction chemotherapy regimen selected by the hypopharyngeal carcinoma patients in historical initial treatment and the total lifetime; then, after a corresponding score cut-off value after preset model training is completed is determined, current multi-modal information of a hypopharyngeal cancer patient subjected to current primary treatment before induced chemotherapy is input into the trained preset model to predict a current risk value, and then a target recommendation scheme for induced chemotherapy is determined based on the current risk value and the score cut-off value. Therefore, the determined target recommended regimen is closer to the actual situation, and the matching degree of the recommended chemotherapy regimen and the actual situation is improved.

Disclosed herein are high performance biomarkers and kits for the early detection of small cell lung cancer (SCLC), which can be used to identify, diagnose and treat SCLC patients in the early stage. Methods of diagnosing and treating SCLC in a subject can include detecting the presence of an autoantibody that specifically binds to one or more epitopes of an antigen in a biological sample obtained from the subject, wherein the one or more epitopes of the antigen comprise a post-translational modification; diagnosing the subject with SCLC when the presence of the autoantibody is detected in the biological sample; and treating the SCLC in the subject by administering a chemotherapy regimen, an immunotherapy regimen, an antibody, surgical and / or radiation therapy. In one example, post-translational modifications targeted by autoantibodies include citrullination, isoaspartic acidification, and / or cancer-specific glycosylation.

The invention discloses a pancreatic cancer prognosis prediction model construction method based on co-expression subtypes of fibroblasts MMP11 and epithelial cells TFF1, and relates to the technical field of pancreatic cancer prognosis models. The pancreatic cancer prognosis prediction model constructed by the invention can comprehensively consider the molecular characteristics and interaction of cells in a tumor microenvironment, accurately predicts the prognosis condition of a patient, provides a reliable basis for a clinician to formulate a personalized treatment scheme, and is helpful for improving the pertinence and effectiveness of treatment. The pancreatic cancer prognosis prediction model constructed by the invention is closely related to chemotherapy drug resistance, and can help a doctor to predict the sensitivity of a patient to chemotherapy drugs in advance, so that invalid chemotherapy is avoided, the pain and economic burden of the patient are reduced, reference is provided for selecting a more suitable chemotherapy regimen, and the curative effect of chemotherapy is improved.

The invention relates to a traditional Chinese medicine composition for treating portal vein and hepatic sinus vascular diseases. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 13-17 parts of astragalus membranaceus, 13-17 parts of angelica sinensis and 4-8 parts of leech. The invention also provides application of the traditional Chinese medicine composition in preparation of medicines for treating portal vein and hepatic sinus vascular diseases. According to the invention, an SD (Sprague Dawley) rat is fed with selenium-rich diet, meanwhile, a model is made according to a chemotherapy regimen of FOLFOX intravenously injected into the tail of the rat every week, the model is made continuously for 8 weeks, a PSVD animal model is copied, the modified Chinese angelica blood replenishing decoction is fed for intervention while the model is made, and simvastatin is taken as a positive control. Results show that the modified Chinese angelica blood replenishing decoction can significantly reduce the portal vein pressure of rats and improve related expressions of liver microangiopathy. The liver index is obviously reduced, and the spleen index is improved. Liver tissue pathological reticular staining and Japanese stellate red staining show that both the liver tissue and the Japanese stellate red staining are relieved.

The present invention relates to the field of genetic engineering technology, and specifically relates to the application of miRNA in the preparation of diagnostic reagents or kits for evaluating breast cancer drug resistance. The present invention has for the first time discovered biomarkers hsa-miR-3646, hsa-miR-4741, hsa-miR-937-5p, hsa-miR-6730-3p, hsa-miR-6831-5p, hsa-miR-8485 that have high diagnostic value for chemotherapy resistance in hormone receptor-positive breast cancer; through the development and application of serum miRNA markers and diagnostic kits, it is possible to detect at an early stage whether breast cancer patients are resistant to traditional chemotherapy regimens, timely change treatment strategies, lay a foundation for clinicians to quickly and accurately grasp the patient's condition, improve individualized precision treatment, and provide assistance for discovering new small molecule drug targets with potential therapeutic value.

The application belongs to the technical field of medical information, and discloses a tumor chemotherapy scheme individualized adjustment and curative effect evaluation method and system. Static basic data, dynamic treatment data, single cell sequencing data and structured data of doctor-patient conversation are comprehensively collected in the data fusion quality control stage. Format adaptation and semantic alignment of cross-modal data are realized through a unified standardized interface. Data quality control is carried out in combination with an isolated forest algorithm, and only high-quality data with a score of 80 or more are included to provide a reliable basis for scheme development. In the multi-module collaborative prediction stage, a medical knowledge graph and a hybrid modeling framework are fused, multi-center data is jointly trained, and drug sensitivity scores are accurately output. When the scheme is generated, the clinical guidelines and patient needs are linked, multi-constraint rule reasoning and multi-objective optimization are used to develop individualized schemes that adapt to the patient's genetic characteristics, pathological types and quality of life demands, and reduce the risk of poor efficacy and serious adverse reactions caused by individual differences.

The present invention relates to a combination therapy regimen of a FAK inhibitor (FAKi) and a FOLFIRINOX chemotherapy regimen, and to the use of this therapy regimen as a means of treating cancer in patients who require cancer treatment, particularly in patients with fibrous cancers / tumors such as pancreatic cancer. Accordingly, the first embodiment provides a method for treating cancer in a subject who requires cancer treatment, comprising administering a combination of a FAK inhibitor (FAKi) and a FOLFIRINOX chemotherapy regimen.

The invention provides a novel human distal bile duct cancer cell line with TP53 missense mutation and application, the novel human distal bile duct cancer cell line CBC3T-3 is established, the cell line is preserved in the China Center for Type Culture Collection (the preservation number is CCTCC NO: C202555), the uniqueness and stability of the cell line are proved through STR typing and karyotype analysis, and the TP53 missense mutation novel human distal bile duct cancer cell line has the advantages that the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3 can be used for preparing the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3; and a plurality of driver gene mutations including TP53 missense mutation are carried. The CBC3T-3 has strong proliferation, invasion and migration capabilities, has high tumor formation rate in immunodeficient mice, is resistant to cis-platinum and sensitive to paclitaxel and gemcitabine, and provides an experimental basis for selection of clinical chemotherapy regimens. According to the model, the TP53 missense mutation type distal bile duct cancer in-vitro model is successfully established, and a key experimental platform is provided for deeply researching the drug resistance mechanism of the TP53 missense mutation type distal bile duct cancer and developing an individualized treatment strategy aiming at the subtype of the TP53 missense mutation type distal bile duct cancer.

This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

The invention discloses an adverse reaction dynamic monitoring and follow-up management system after chemotherapy, and relates to the technical field of data processing, and the system comprises an acquisition module which determines a to-be-monitored symptom and a corresponding target part according to a chemotherapy regimen of a patient, and receives an image of the target part; the recognition module carries out registration on the part partition map and the target part image, a reaction partition with an abnormal color block area is determined, and color block positioning points are marked; the analysis module generates a positioning acquisition frame according to the part partition to which the color block positioning points belong, receives the review part image, cuts the target part image and the review part image based on the positioning acquisition frame, and determines the point location diffusion amount; and the decision-making module determines a follow-up visit mode according to the point location diffusion amount and the partition position of the reaction partition. The patient is guided to review and shoot the same position through the positioning collection frame, the follow-up visit mode is determined in combination with the partition positions, and the accuracy of follow-up visit decision is improved.

The invention discloses an AML chemotherapy regimen sharing method and system based on distributed processing, and belongs to the technical field of medical information. The method comprises the following steps: acquiring clinical data related to an AML chemotherapy regimen, including patient information, pathological indexes and iconography data, performing preprocessing and semantic annotation, and generating a semantic clinical data unit with a distributed identifier; registering the identifier, the metadata and the digital signature to a distributed account book network maintained by multiple mechanisms; receiving a query request based on the semantic tag and the metadata, and matching a data unit in an account book network through a semantic engine; and after verifying the authority of the requester, transmitting a data load or executing a distributed computing task of which the data cannot be out of the domain through the secure channel. The problems of privacy security, cross-mechanism interoperation and credible authentication in clinical data sharing are effectively solved, and an efficient and reliable data collaboration platform is provided for AML diagnosis and treatment research.

The invention discloses a method for performing drug sensitivity detection by using a patient-derived micro-tumor cell cluster (PTC) and assisting a gastric cancer patient in accurately selecting a chemotherapy regimen, and particularly relates to a method for performing drug sensitivity detection by using a patient-derived micro-tumor cell cluster (PTC). The method comprises the following steps: constructing a PTC micro-tumor by using fresh surgery, biopsy or malignant effusion samples of a patient, co-culturing PTC and four common gastric cancer drug schemes of PF, XELOX, TF and DF for 168 hours, comparing the PTC area change ratio PA before and after co-culture, evaluating the drug killing efficiency of different drug schemes on PTC, and assisting the patient in accurately selecting a chemotherapy scheme in combination with clinical actual conditions. Compared with other methods, the method has the advantages that the tumor microenvironment can be simulated more truly, so that the drug sensitivity detection result based on the method is close to the clinical real situation, and individualized precise medical service is better provided.

The invention relates to the technical field of medicines, and discloses application of sanggenol L in preparation of a medicine for treating chemotherapy-resistant small cell lung cancer. The invention also provides a medicine containing sanggenol L and used for treating chemotherapy resistant small cell lung cancer. The invention finds that sanggenol L is targeted to Cx32 protein so as to reverse the chemotherapy drug resistance of SCLC to CDDP and VP-16 in an EP chemotherapy regimen, and provides a new safe and effective drug combination strategy.

The present disclosure relates to methods of treating cancer in a subject by administering to the subject effective amounts of an anti-CCR8 antibody, a chemotherapeutic agent (e.g., cisplatin, gemcitabine, docetaxel), and a PD1 inhibitor or a PD-L1 inhibitor. In some embodiments, the chemotherapeutic agent is administered at a lower dose than in a standard of care chemotherapy regimen that does not include the anti-CCR8 antibody. In some embodiments, the chemotherapeutic agents are co-administered at a lower dose than in a standard of care chemotherapy regimen that does not include the anti-CCR8 antibody.

The invention provides application of a CD5-targeting reagent in the aspects of reducing the drug resistance of tumor cells and improving the anti-tumor curative effect of drugs, and clarifies for the first time that CD5 molecules can promote high expression and cell nucleus displacement of transcription factors FOXO3a and FOXO4 in a forkhead cassette O signal channel; therefore, expression increase of the ABC drug-resistant protein family in diffuse large B-cell lymphoma tumor cells is mediated, and drug resistance of tumor cells to various chemotherapeutic drugs is promoted. Further, it is found that the celecoxib can significantly inhibit expression of CD5 molecule mediated ABC drug-resistant protein in B-cell lymphoma cells, then the celecoxib and chemotherapeutic drugs are combined for application, the killing effect of traditional chemotherapeutic drugs on diffuse large B-cell lymphoma tumor cells is significantly enhanced, and the chemotherapeutic drug resistance of diffuse large B-cell lymphoma is overcome. The anti-drug-resistant tumor strategy can overcome the problems of low treatment response rate and poor prognosis of the CD5-positive diffuse large B-cell lymphoma to the existing chemotherapy regimen due to multidrug resistance, and significantly improves the anti-tumor treatment effect.

The invention discloses an anti-osteosarcoma combined pharmaceutical composition and application thereof. The combined pharmaceutical composition comprises a TNF alpha inhibitor and a chemotherapeutic drug. According to the invention, the TNF alpha inhibitor and the traditional chemotherapeutic drug are combined for use for the first time to resist osteosarcoma, so that the purposes of synergistic tumor inhibition, toxicity reduction and sensitization are achieved. By intervening a neglected chemotherapy side reaction pathway of tumor-liver axis, tumor-derived extracellular vesicles are blocked to induce Kupffer cells to release TNF alpha, liver lipid droplet deposition is reduced, and expression (including Cyp1a2, Cyp2b10, Cyp3a11 and the like) of CYP metabolic enzymes is recovered, so that the metabolic capability of the liver to chemotherapy drugs is improved, and toxic and side effects are reduced. From the perspective of chemotherapy tolerance and toxic and side effect control, cardiotoxicity and myelosuppression are remarkably reduced, the overall tolerance to a chemotherapy regimen is improved, and a safer and more efficient strategy is provided.

Extranodal natural killer / T-cell lymphoma (ENKTCL) is an aggressive haematological malignancy. The treatment of ENKTCL is dependent on the extent of the tumor. However the use of L-asparaginase-containing regimens obtained impressive outcomes as induction or salvage treatment for ENKTCL. Although more than 70% of early-stage patients can achieve long-term survival, patients with advanced-stage disease had extremely poor prognosis even after asparaginase-based chemotherapy regimens. There is thus a medical need for improving the treatment of ENKTCL with L-asparaginase. Now the inventors demonstrate the interest of the use of L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL. In particular, combination of APR-246 and Erwinase R has synergistic effects in KHYG-1 cells. The present invention thus relates to the use of a L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL.

The invention discloses a method for improving chemotherapy efficiency of a tumor department. The method comprises the following steps that a whole disease course management system is utilized, after a chemotherapy regimen of a patient is determined, individual case management and the patient confirm follow-up return time, within effective time before the return time, the system will inform a user to complete specified biochemical inspection, the patient uploads an effective inspection list to the system, and the system automatically judges whether the condition of next chemotherapy is met or not; submitting examinations and medical records of the patients meeting the conditions to doctors of the daytime chemotherapy center, and making prescriptions by the doctors according to results; the system informs the patient of exact hospital return date and time and appointment a bed, the patient directly checks in the daytime chemotherapy center according to appointment prompts in the system after arriving at the hospital, the daytime chemotherapy center confirms that elements are complete, medicines are directly dispensed, infusion is arranged, and the patient can directly leave the hospital after infusion is finished. The method has the beneficial effects that the preparation time of a patient before chemotherapy is shortened; the extra expenditure of outpatient service is reduced; the bed utilization efficiency is improved.

Methods of treating gastric cancer or gastroesophageal junction cancer in subjects are described. The methods may comprise administering an anti-FGFR2b antibody to the subject. The methods may further comprise administering a chemotherapy regimen comprising (a) oxaliplatin and capecitabine; or (b) oxaliplatin and S-1 to the subject.

The invention belongs to the technical field of application of traditional Chinese medicine preparations, and discloses application of Jinshuiliujun decoction in preparation of a medicine for treating EGFR sensitive mutation non-small cell lung cancer, the medicine is used for being applied in combination with chemotherapy, a classic traditional Chinese medicine compound is combined with a modern chemotherapy regimen, and when a patient suffering from IIIb / IV-stage EGFR sensitive mutation is treated, the curative effect is good, and the curative effect is good. The pharmaceutical composition shows clear synergistic interaction and toxicity reduction effects, and the specific performance is as follows: the median progression-free lifetime of a patient is obviously prolonged; the traditional Chinese medicine syndromes such as cough and weakness are improved; the immunologic function is effectively regulated, and the CD4 + / CD8 + ratio is increased; the negative emotion score of the patient is reduced; the adverse reaction incidence rate of chemotherapy is not increased; a brand new traditional Chinese and western medicine combined treatment scheme is provided for the specific lung cancer subtype, and the curative effect and life quality are improved.

Despite aggressive radio / chemotherapy regimens, pediatric high-grade gliomas (pHGG) are deadly brain tumors that remain incurable and are the leading cause of cancer-related death in children. By analysing the impact of H3.3 mutations on DNA repair and genome integrity maintenance capacities of glioma cells, the present inventors identified the PNKP enzyme as being a major protein partner interacting with mutated H3 oncohistone specifically, and involved in DNA aberrant repair. They showed that inhibition of this enzyme prevents the proliferation of glioma tumor cells bearing specific H3 oncohistone mutations. They therefore propose to target this enzyme in order to efficiently treat patients suffering from gliomas, in particular pediatric gliomas bearing these specific H3 oncohistone mutations, or to sensitize them to current radio / chemotherapeutic regimens, for which there is very limited response.

To provide a method for treating a host with a cancer or tumor that increases the preservation of the host's innate immune system during and / or after chemotherapy.SOLUTION: The addition of a selective, fast-acting, short half-life CDK 4 / 6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4 / 6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.SELECTED DRAWING: Figure 1

The invention discloses a diagnosis and treatment target device for cytophagic lymphocytosis. The device comprises a detection module, a detection module and a control module, wherein the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2 in a patient sample of a current patient; the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2; the analysis module is used for carrying out difference analysis on the expression quantity and the expression quantity of a healthy control group to obtain a molecular characteristic spectrum related to the HLH; the diagnosis typing treatment module is used for performing diagnosis typing on the current patient according to a difference mode of the molecular characteristic spectrum and treating according to a diagnosis typing result, so that serious treatment toxicity such as myelosuppression and liver and kidney injury of a traditional chemotherapy regimen can be reduced, the safety and effectiveness of clinical treatment of the patient are improved, and higher specificity and accuracy are achieved; a foundation is laid for developing a novel diagnostic tool, and a direct and feasible candidate scheme and a theoretical basis are provided for developing a high-efficiency and low-toxicity HLH new therapy.

Use of a pharmaceutical composition comprising retinoic acid in preparing a drug for treating hepatocellular carcinoma accompanied by abdominal cavity metastasis. The pharmaceutical composition comprises an FOLFOX4 chemotherapy regimen and retinoic acid. The FOLFOX4 chemotherapy regimen is a primary active ingredient for treating hepatocellular carcinoma accompanied by abdominal cavity metastasis. The retinoic acid is an auxiliary ingredient used for enhancing the FOLFOX4 chemotherapy regimen in treating hepatocellular carcinoma accompanied by abdominal cavity metastasis. The FOLFOX4 chemotherapy regimen consists of oxaliplatin, 5-fluorouracil, and calcium folinate. In the aspect of treating hepatocellular carcinoma accompanied by abdominal cavity metastasis, the pharmaceutical composition of the present invention exhibits significantly superior efficacy compared to equivalent doses of the FOLFOX4 chemotherapy regimen alone and the retinoic acid alone, indicating that the combined use of the two has a significant synergistic effect.

A system for remote assessment of clinical response and dynamic optimization of the chemotherapy regimen in oncology, consisting of: a device for clinical assessment of patient response, designed as a physical machine structure with a housing for use on the body or at the bedside; a housing-mounted physiological sensor unit configured to record continuous or periodic measurements of heart rate, heart rate variability, respiratory rate, peripheral oxygen saturation, body temperature, physical activity and sleep-related parameters of an oncology patient during chemotherapy; a biochemical sensor unit integrated into the housing, configured to detect biochemical indicators related to response to chemotherapy and toxicity, including inflammatory markers, metabolic indicators, hematological trends or drug-related metabolites; a patient interaction unit configured to receive symptom data reported by the patient, corresponding to treatment tolerability and functional status; an embedded processing unit that is operationally connected to the physiological sensor unit, the biochemical sensor unit, and the patient interaction unit, and is configured to perform signal conditioning, temporal alignment, data integrity verification, and encryption of the acquired patient data; a communication unit that is operationally connected to the embedded processing unit and configured to transmit the processed patient data to a remote processing infrastructure using secure communication protocols; a remote processing system comprising at least one processing unit and a storage unit for storing executable instructions, wherein the processing unit is configured to aggregate longitudinal patient data across chemotherapy cycles, analyze correlations between recorded physiological data, biochemical indicators, patient-reported outcomes, and parameters of chemotherapy administration, and calculate a clinical assessment of response; and A system for interacting with physicians, configured to display the results of the clinical response assessment and generate recommendations for optimizing the chemotherapy regimen, which are subject to review and approval by the physician.

The addition of a selective, fast-acting, short half-life CDK 4 / 6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4 / 6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.

Disclosed herein are high-performance biomarkers and panels for the early detection of small cell lung cancer (SCLC), which are useful for identifying, diagnosing, and treating SCLC patients at an early stage. A method for diagnosing and treating SCLC in a subject includes detecting the presence of an autoantibody that specifically binds to one or more epitopes of an antigen in a biological sample obtained from the subject, where the one or more epitopes of the antigen comprise a post-translational modification; diagnosing the subject as having SCLC if the presence of the autoantibody is detected in the biological sample; and treating the SCLC in the subject by administering a chemotherapy regimen, an immunotherapy regimen, an antibody, performing surgery, and / or performing radiation therapy. In one example, the post-translational modifications targeted by the autoantibody include citrullination, isoaspartylation, and / or cancer-specific glycosylation.

Disclosed in the present invention are a pharmaceutical composition and the use thereof. The pharmaceutical composition of the present invention comprises linperlisib or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, and a chemotherapy regimen drug. The pharmaceutical composition of the present invention is used for the first-line treatment of PTCL. The pharmaceutical composition may provide faster and deeper remission, prolong survival time, have better efficacy and safety in treatment-naive PTCL patients, and can greatly address the unmet clinical needs.